{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-23-014829","form_type":"8-K","ticker":null,"cik":"0001614067","company_name":"Aridis Pharmaceuticals, Inc.","filed_at":"2023-05-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:39.669548+00:00","generated_at":"2026-06-16T05:03:11.700586+00:00","sec_items":["1.01","2.03","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Aridis Pharmaceuticals enters $9.3M note restructuring with Streeterville Capital, $2.5M new funding","bullets":["Secured note principal up to $9.29M; $1M direct draw at closing, $1.5M escrowed for future draws.","Interest at 8% per annum; maturity April 26, 2024; amortization of 16.67% monthly starting October 26, 2023.","Covenants include maintaining Nasdaq listing, filing SEC reports, and no restricted issuances without Investor consent.","Prepayment at 110% of outstanding balance; proceeds from JV sale or equity offering trigger mandatory prepayment.","Prior note #2 ($5.25M original principal) cancelled; outstanding balance affirmed at $2.67M."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-23-014829","json":"https://secwatch.observer/filing/0001493152-23-014829.json","markdown":"https://secwatch.observer/filing/0001493152-23-014829.md","text":"https://secwatch.observer/filing/0001493152-23-014829.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1614067/000149315223014829/0001493152-23-014829-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1614067/000149315223014829/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-16T05:03:11.700586+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ee73aa2982048fab0119a5727c0c519c6b69dcc5","claim":"Aridis Pharmaceuticals, Inc. incurred loan of up to $9,286,770.80 with Streeterville Capital, LLC at 8% per annum maturing April 26, 2024.","evidence_excerpt":"Pursuant to the Agreement, the Investor agreed to invest an additional investment amount of up to $2,500,000, $1,000,000 of which will delivered to the Company at closing and the remaining $1,500,000 of which will be placed into escrow under a secured line of credit facility with the total original principal amount of the secured promissory note being up to $9,286,770.80 (the “Secured Note”).","evidence_source":"SEC 8-K Item 2.03/2.04","evidence_url":"https://www.sec.gov/Archives/edgar/data/1614067/000149315223014829/0001493152-23-014829-index.htm","confidence":0.9,"family_label":"Debt Financings","details":[{"label":"Instrument","value":"loan"},{"label":"Principal","value":"up to $9,286,770.80"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Rate","value":"8% per annum"},{"label":"Maturity","value":"April 26, 2024"},{"label":"Event","value":"incurrence"}],"fact_type":"debt_financing"},{"claim_id":"9b59a351b47b8da841a3dca726c8f95fe3f0bd69","claim":"Aridis Pharmaceuticals, Inc. entered into Note Purchase and Loan Restructuring Agreement with Streeterville Capital, LLC valued at up to $2,500,000 additional investment, total principal up to $9,286,770.80 (effective 2023-04-26).","evidence_excerpt":"On April 26, 2023, Aridis Pharmaceuticals, Inc. (the “Company”) entered into a Note Purchase and Loan Restructuring Agreement (the “Agreement”) with Streeterville Capital, LLC (the “Investor”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1614067/000149315223014829/0001493152-23-014829-index.htm","confidence":0.95,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"credit facility"},{"label":"Counterparty","value":"Streeterville Capital, LLC"},{"label":"Value","value":"up to $2,500,000 additional investment, total principal up to $9,286,770.80"},{"label":"Effective","value":"2023-04-26"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}